

Controversy: What is the optimal GVHD prophylaxis in T-cell repleted haploidentical transplantation? – Post Cy

Christopher Kanakry

USA

Post-transplantation cyclophosphamide (PTCy) has been widely and rapidly adopted as graft-versus-host disease (GVHD) prophylaxis after T-cell-replete human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (HCT), and PTCy also is becoming increasingly used as GVHD prophylaxis for HLA-matched HCT. PTCy's broad appeal is due to it being an inexpensive approach that does not require specialized technology or infrastructure, yet also being highly effective at substantially decreasing the rates of both severe acute GVHD and chronic GVHD. Corresponding to the decreased incidence and severity of GVHD, the amount of other immunosuppression required is quite minimal, promoting immune reconstitution that effectively prevents severe opportunistic infections, such as cytomegalovirus disease or Epstein-Barr-virus-related post-transplantation lymphoproliferative disease, further decreasing transplant-related mortality.